A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer
ObjectiveThe objective of this study was to assess the effectiveness and safety of CDK4/6 inhibitors in the treatment of hormone receptor-positive (HR+) breast cancer by using meta-analysis.MethodsTo gather comprehensive and reliable data for our analysis, we systematically searched multiple databas...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1472407/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850074814010621952 |
|---|---|
| author | Jialin Zhang Xinyu Xu Yeyue Zhou Jingyang Su Jue Wang |
| author_facet | Jialin Zhang Xinyu Xu Yeyue Zhou Jingyang Su Jue Wang |
| author_sort | Jialin Zhang |
| collection | DOAJ |
| description | ObjectiveThe objective of this study was to assess the effectiveness and safety of CDK4/6 inhibitors in the treatment of hormone receptor-positive (HR+) breast cancer by using meta-analysis.MethodsTo gather comprehensive and reliable data for our analysis, we systematically searched multiple databases for relevant studies. We utilized RevMan5.3 software to perform the meta-analysis.ResultsFollowing a rigorous screening and evaluation process, we ultimately included a total of 13 studies in our analysis. Our findings showed that compared to endocrine therapy alone, the combination of CDK4/6 inhibitors with endocrine therapy significantly increased both PFS [HR 0.54 (95%CI: 0.50, 0.58), P<0.00001], OS [HR 0.77 (95%CI: 0.50, 0.58), P<0.00001] and ORR [RR 1.39 (95% CI: 1.21, 1.60), P<0.00001). However, it was also found that CDK4/6 inhibitors caused adverse drug reactions related to the blood system and digestive system (P<0.0001).ConclusionsOur meta-analysis demonstrates that the addition of CDK4/6 inhibitors to endocrine therapy can result in improved PFS and OS for HR+ breast cancer patients. Meanwhile, we recommend close monitoring and management of these potential side effects when utilizing these inhibitors in breast cancer treatment.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO, identifier CRD42023490499. |
| format | Article |
| id | doaj-art-6b582a1df25b4e2d8f392d63c2c5ce8e |
| institution | DOAJ |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-6b582a1df25b4e2d8f392d63c2c5ce8e2025-08-20T02:46:28ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-03-011510.3389/fonc.2025.14724071472407A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancerJialin Zhang0Xinyu Xu1Yeyue Zhou2Jingyang Su3Jue Wang4Department of Oncology, Hangzhou TCM Hospital of Zhejiang Chinese Medical University (Hangzhou Hospital of Traditional Chinese Medicine), Hangzhou, ChinaDepartment of Oncology, Hangzhou TCM Hospital of Zhejiang Chinese Medical University (Hangzhou Hospital of Traditional Chinese Medicine), Hangzhou, ChinaDepartment of Oncology, Hangzhou TCM Hospital of Zhejiang Chinese Medical University (Hangzhou Hospital of Traditional Chinese Medicine), Hangzhou, ChinaDepartment of General internal medicine, Tongde Hospital Affiliated to Zhejiang Chinese Medical University (Tongde Hospital of Zhejiang Province), Hangzhou, ChinaDepartment of Oncology, Hangzhou TCM Hospital of Zhejiang Chinese Medical University (Hangzhou Hospital of Traditional Chinese Medicine), Hangzhou, ChinaObjectiveThe objective of this study was to assess the effectiveness and safety of CDK4/6 inhibitors in the treatment of hormone receptor-positive (HR+) breast cancer by using meta-analysis.MethodsTo gather comprehensive and reliable data for our analysis, we systematically searched multiple databases for relevant studies. We utilized RevMan5.3 software to perform the meta-analysis.ResultsFollowing a rigorous screening and evaluation process, we ultimately included a total of 13 studies in our analysis. Our findings showed that compared to endocrine therapy alone, the combination of CDK4/6 inhibitors with endocrine therapy significantly increased both PFS [HR 0.54 (95%CI: 0.50, 0.58), P<0.00001], OS [HR 0.77 (95%CI: 0.50, 0.58), P<0.00001] and ORR [RR 1.39 (95% CI: 1.21, 1.60), P<0.00001). However, it was also found that CDK4/6 inhibitors caused adverse drug reactions related to the blood system and digestive system (P<0.0001).ConclusionsOur meta-analysis demonstrates that the addition of CDK4/6 inhibitors to endocrine therapy can result in improved PFS and OS for HR+ breast cancer patients. Meanwhile, we recommend close monitoring and management of these potential side effects when utilizing these inhibitors in breast cancer treatment.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO, identifier CRD42023490499.https://www.frontiersin.org/articles/10.3389/fonc.2025.1472407/fullbreast cancerCDK4/6 inhibitorsAbemaciclibPalbociclibRibociclibDalpiciclib |
| spellingShingle | Jialin Zhang Xinyu Xu Yeyue Zhou Jingyang Su Jue Wang A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer Frontiers in Oncology breast cancer CDK4/6 inhibitors Abemaciclib Palbociclib Ribociclib Dalpiciclib |
| title | A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer |
| title_full | A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer |
| title_fullStr | A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer |
| title_full_unstemmed | A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer |
| title_short | A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer |
| title_sort | meta analysis and systematic review of different cyclin dependent kinase 4 6 inhibitors in breast cancer |
| topic | breast cancer CDK4/6 inhibitors Abemaciclib Palbociclib Ribociclib Dalpiciclib |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1472407/full |
| work_keys_str_mv | AT jialinzhang ametaanalysisandsystematicreviewofdifferentcyclindependentkinase46inhibitorsinbreastcancer AT xinyuxu ametaanalysisandsystematicreviewofdifferentcyclindependentkinase46inhibitorsinbreastcancer AT yeyuezhou ametaanalysisandsystematicreviewofdifferentcyclindependentkinase46inhibitorsinbreastcancer AT jingyangsu ametaanalysisandsystematicreviewofdifferentcyclindependentkinase46inhibitorsinbreastcancer AT juewang ametaanalysisandsystematicreviewofdifferentcyclindependentkinase46inhibitorsinbreastcancer AT jialinzhang metaanalysisandsystematicreviewofdifferentcyclindependentkinase46inhibitorsinbreastcancer AT xinyuxu metaanalysisandsystematicreviewofdifferentcyclindependentkinase46inhibitorsinbreastcancer AT yeyuezhou metaanalysisandsystematicreviewofdifferentcyclindependentkinase46inhibitorsinbreastcancer AT jingyangsu metaanalysisandsystematicreviewofdifferentcyclindependentkinase46inhibitorsinbreastcancer AT juewang metaanalysisandsystematicreviewofdifferentcyclindependentkinase46inhibitorsinbreastcancer |